Welcome to our dedicated page for Priveterra Acqsn news (Ticker: PMGMU), a resource for investors and traders seeking the latest updates and insights on Priveterra Acqsn stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Priveterra Acqsn's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Priveterra Acqsn's position in the market.
Priveterra Acquisition Corp. II (NASDAQ: PMGMU, PMGM, PMGMW) received a notice from Nasdaq due to the late filing of its Annual Report on Form 10-K for the period ended December 31, 2023. The delinquency may lead to delisting of the Company's securities from Nasdaq, and the Nasdaq Hearings Panel will review the matter. The Company must submit its views in writing by May 6, 2024.
Priveterra Acquisition Corp. announced it received a notice from Nasdaq on May 28, 2021, due to its failure to timely file its Quarterly Report for the period ending March 31, 2021. This notice indicates non-compliance with Nasdaq Listing Rule 5250(c)(1), although it does not affect the trading status of its securities immediately. The company plans to submit a compliance plan within 60 days, with potential to regain compliance by November 22, 2021, if accepted. The late filing stems from the SEC's recent directive regarding the accounting treatment of warrants, which the company is currently assessing.
Priveterra Acquisition Corp. (Nasdaq: PMGMU) announced that, starting April 1, 2021, holders of units from its IPO can separately trade Class A common stock and warrants. The common stock will trade under the symbol 'PMGM' and warrants under 'PMGMW.' Only whole warrants will be issued, with no fractional warrants available. The company, aimed at acquiring a business in medical technology, listed Wells Fargo Securities and Guggenheim Securities as joint book-runners for the offering. This news does not constitute an offer to sell securities.
Priveterra Acquisition Corp. (Nasdaq: PMGMU) successfully closed its IPO, raising $276 million by offering 27.6 million units at $10.00 each. Trading of the units began on February 9, 2021, with each unit comprising one share of Class A common stock and one-third of a redeemable warrant, the latter exercisable at $11.50 per share. The company, which focuses on the healthcare sector, will use proceeds for potential mergers and acquisitions. The offering was managed by Wells Fargo Securities and Guggenheim Securities.
Priveterra Acquisition Corp. announced the pricing of its initial public offering (IPO) of 24 million units at $10.00 each, set to trade under the ticker symbol PMGMU starting February 9, 2021. Each unit includes one share of Class A common stock and a third of a redeemable warrant. The company is a blank-check firm targeting the healthcare sector, particularly medical technology. Wells Fargo and Guggenheim Securities lead the offering, with an option for underwriters to purchase an additional 3.6 million units. The registration statement was effective as of February 8, 2021.
